Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
figureposted on 2021-03-10, 17:20 authored by Adis journals on behalf of, Victoria Wurcel, Diana Chirovsky, Rebekah Borse, Juan Ignacio Altuna, Fernando Carabajal, Jyotika Gandhi
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.